Literature DB >> 18452468

Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on night-time urine production.

Shinsuke Okada1, Hideki Watanabe, Yoshiyuki Kojima, Yoshimasa Yanai, Shoichi Sasaki, Kenjiro Kohri.   

Abstract

We evaluated the efficacy of loxoprofen sodium for refractory nocturia. Twelve men (mean age, 75.1 +/- 5.7) with nocturia were enrolled in this study. All patients received 60 mg loxoprofen sodium prior to sleeping at night for 14 days. Nine of 12 patients (75%) felt more satisfaction than previous treatments. Patients were grouped into a loxoprofen sodium-effective (n = 7) and ineffective groups (n = 5) based on the results of the frequency-volume chart. In the effective group, interestingly, night-time urine volume showed significant reduction (P < 0.05). On the other hand, the average single voided volume at night and 24-h urine volume showed no significant change. There was a statistically significant difference in the night-time urine volume after treatment between groups (P < 0.01). Loxoprofen sodium is an effective treatment for some patients with refractory nocturia. The main effect mechanism of loxoprofen sodium may involve the reduction of night-time urine production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452468     DOI: 10.1111/j.1442-2042.2008.02021.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

1.  Long-term effect of loxoprofen sodium on nocturia in patients with benign prostatic hyperplasia.

Authors:  Hong Il Shin; Byung Hoon Kim; Hyuk Soo Chang; Choal Hee Park; Chun Il Kim
Journal:  Korean J Urol       Date:  2011-04-22

2.  Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Authors:  Takashi Kawahara; Satoshi Morita; Hiroki Ito; Hideyuki Terao; Ryoko Sakata; Hitoshi Ishiguro; Katsuyuki Tanaka; Hiroshi Miyamoto; Junichi Matsuzaki; Yoshinobu Kubota; Hiroji Uemura
Journal:  BMC Urol       Date:  2013-06-12       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.